个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang Jun[1] ; Zhang Bicheng[2] ; Peng Ling[3] ; Liu Xiufeng[4] ; Sun Jianguo[5] ; Su Chunxia[6] ; Wang Huijuan[7] ; Zhao Zheng[8] ; Si Lu[9] ; Duan Jianchun[10] ; Zhang Hongmei[11] ; Li Mengxia[12] ; Zhu Bo[5] ; Zhang Li[13] ; Li Jin[14] ; Guo Jun[9] ; Luo Rongcheng[15] ; Qiu Wensheng[16] ; Ye Dingwei[17] ; Chu Qian[18] ; Cui Jiuwei[19] ; Dong Xiaorong[20] ; Fan Yun[21] ; Gao Quanli[22] ; Guo Ye[14] ; He Zhiyong[23] ; Li Wenfeng[24] ; Lin Gen[23] ; Liu Lian[25] ; Liu Yutao[10] ; Qin Haifeng[26] ; Ren Shengxiang[6] ; Ren Xiubao[27] ; Wang Yongsheng[28] ; Xue Junli[14] ; Yang Yunpeng[13] ; Yang Zhenzhou[29] ; Yue Lu[30] ; Zhan Xianbao[31] ; Zhang Junping[32] ; Ma Jun[33] ; Qin Shukui[34] ; Wang Baocheng[35] ;
机构： [1]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan 250014, China. [2]Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. [3]Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Hangzhou, China. [4]Department of Hepatobiliary Oncology, Qinhuai Medical District, Eastern Theater Command General Hospital, Nanjing, China. [5]Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China. [6]Department of Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. [7]Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. [8]Department of Oncology, Shannxi Cancer Hospital, Xi'an, China. [9]Department of Melanoma, Cancer Hospital and Institute, Peking University, Beijing, China. [10]Department of Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. [11]Department of Oncology, Xijing Hospital, Air Force Medical University, Xian, China. [12]Cancer Center, Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing, China. [13]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, China. [14]Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. [15]Cancer Center, Jinshazhou Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China. [16]Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China. [17]Department of Urology, Shanghai Cancer Center, Fudan University, Shanghai, China. [18]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [19]Department of Oncology, The First Hospital of Jilin University, Changchun, China. [20]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [21]Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China. [22]Department of Immunology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. [23]Department of Thoracic Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China. [24]Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. [25]Department of Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. [26]Department of Oncology, Chinese People's Liberation Army General Hospital, Beijing, China. [27]Department of Immunology and Biotherapy, Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China. [28]GCP Center/Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China. [29]Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. [30]Department of Oncology, Qingdao Municipal Hospital, Qingdao, China. [31]Department of Oncology, Changhai Hospital, Navy Medical University, Shanghai, China. [32]Department of Cancer Biotherapy, Shanxi Bethune Hospital, Taiyuan, China. [33]Harbin Institute of Hematology and Oncology, Harbin, China. [34]Department of Hepatobiliary Oncology, Qinhuai Medical District, Eastern Theater Command General Hospital, Nanjing 210008, China. [35]Department of Oncology, The 960th Hospital, The People's Liberation Army, Jinan 250031, China.
出处：
DOI： 10.1177/17588359231187205
ISSN：

关键词： Chinese Society of Clinical Oncology consensus immune checkpoint inhibitor recommendation special population

摘要：
Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442-454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology.© The Author(s), 2023.

基金：
This work was supported by the Chinese Society of Clinical Oncology (CSCO).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan 250014, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Jun,Zhang Bicheng,Peng Ling,et al.Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations[J].Therapeutic Advances In Medical Oncology.2023,15:17588359231187205.doi:10.1177/17588359231187205.
APA：
Wang Jun,Zhang Bicheng,Peng Ling,Liu Xiufeng,Sun Jianguo...&Wang Baocheng.(2023).Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.Therapeutic Advances In Medical Oncology,15,
MLA：
Wang Jun,et al."Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations".Therapeutic Advances In Medical Oncology 15.(2023):17588359231187205

相关文献

[1]Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(Open Access) [2]Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer [3]The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. [4]The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 [5]The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. [6]The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma [7]ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. [8]人乳头瘤病毒疫苗临床应用中国专家共识 [9]Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma [10]Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号